Eric Bernicker

COVID-19 in Patients With Gynecologic Cancer: A Report From the COVID-19 and Cancer Consortium

Alaina J. Brown, Chih-Yuan Hsu, Aleenah Mohsin, Lauren S. Prescott et autres

PURPOSE: Limited information exists regarding outcome severity among gynecologic cancer patients with SARS-CoV-2 infection. The objective of this study was to describe patient, cancer, and COVID-19 characteristics, and to identify factors associated with COVID-19 severity. METHODS: Gynecologic cancer patients with SARS-CoV-2 infection …

us, mx (code pays fourni par la source)

A phase I trial of intratumoral adenovirus-interleukin-12 (IT-ADV/IL-12) and atezolizumab in metastatic non-small cell lung cancer (NSCLC) progressed on first-line immunotherapy.

Zainub Ajmal, Jian Guan, Jitesh Joshi, Eric Bernicker et autres

8551 Background: Interleukin-12 (IL-12) is a cytokine that enhances anti-tumor immunity via interferon-gamma release and has demonstrated synergistic effects with immune checkpoint inhibitors (ICIs) in immunoquiescent tumors. We report results of phase I trial of intratumoral adenovirus-interleukin-12(IT-ADV/IL-12)plus atezolizumab in metastatic NSCLC patients …

us (code pays fourni par la source)

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium

Christopher McNair, Vadim S. Koshkin, Maryam B. Lustberg, Douglas B. Johnson et autres

Effect of direct oral anticoagulants compared to enoxaparin on objective response to immune checkpoint inhibitors in patients with lung cancer

Solmaz Karimi, Karen Abboud, Godsfavour Umoru, Eric Bernicker

IntroductionA hypoxic tumor microenvironment inhibits the normal functioning of immune cells. Studies have hypothesized that anticoagulants that can penetrate and bind to factor Xa in the tumor microenvironment, can enhance T-cell function and augment immunotherapy activity. This study compared objective response rate …

us (code pays fourni par la source)

Use of combined chemotherapy and immunotherapy improves pulmonary arterial hypertension

T. P. Reddy, Roberto Barrios, Eric Bernicker, Wei Qian et autres

Treatment modalities for pulmonary arterial hypertension (PAH) improve quality of life and walk distance. However, none of these therapies alter the structural/functional pulmonary vascular integrity that results in vascular remodeling. PAH smooth muscle cells share biological characteristics with cancer cells, which may …

us (code pays fourni par la source)

5-hydroxymethylcytosine in cell-free DNA as liquid biomarker for immune checkpoint inhibitor therapy in non–small cell lung cancer.

Zainub Ajmal, Jianming Shao, Randall J. Olsen, Saro Kasparian et autres

e20563 Background: Immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1), and its ligand (PD-L1) are the mainstay of treatment for metastatic non-small cell lung cancer (NSCLC) in patients lacking targetable driver mutations. However, optimal predictive biomarkers are lacking. We used …

us (code pays fourni par la source)

5-Hydroxymethylcytosine in Cell-Free DNA Predicts Immunotherapy Response in Lung Cancer

Jianming Shao, Yitian Xu, Randall J. Olsen, Saro Kasparian et autres

Immune checkpoint inhibitors (ICIs) drastically improve therapeutic outcomes for lung cancer, but accurately predicting individual patient responses to ICIs remains a challenge. We performed the genome-wide profiling of 5-hydroxymethylcytosine (5hmC) in 85 plasma cell-free DNA (cfDNA) samples from lung cancer patients and …

us (code pays fourni par la source)

Cell-Free DNA 5-Hydroxymethylcytosine Signatures for Lung Cancer Prognosis

Jianming Shao, Randall J. Olsen, Saro Kasparian, Chuan He et autres

Accurate prognostic markers are essential for guiding effective lung cancer treatment strategies. The level of 5-hydroxymethylcytosine (5hmC) in tissue is independently associated with overall survival (OS) in lung cancer patients. We explored the prognostic value of cell-free DNA (cfDNA) 5hmC through genome-wide …

us (code pays fourni par la source)

Climate Change and Cancer Care: A Policy Statement From ASCO

Eric Bernicker, Steve D. Averbuch, Stephen B. Edge, Jasmine Kamboj et autres

There is incontrovertible and increasing evidence that the changing climate because of the production and burning of fossil fuels has impact on health care delivery and outcomes around the world.Recently, global publications and professional medical societies, including the American Medical Association, have …

us, lb (code pays fourni par la source)

1234 Impact of infections in patients receiving immune checkpoint inhibitor therapies for non-small cell lung cancer (NSCLC)

Kelly Gee, Catherine Wiechmann, Ethan Burns, Jiaqiong Xu et autres

Background While infections are a known cause of morbidity and mortality in those receiving chemotherapy, the burden of infections in the ICI era is seldom explored. This analysis aimed to assess incidence of infections and risk factors in patients who received pembrolizumab …

us (code pays fourni par la source)

OA04.05 To Treat or Not to Treat: Factors Impacting Treatment Decisions in Octogenarians with Non-Small Cell Lung Cancer (NSCLC)

Wei-Hsin Chen, Ethan Burns, Shreya Mathur, Ryan Blair Kieser et autres

us (code pays fourni par la source)

61. A cell-free DNA 5-hydroxymethylcytosine marker predicts immunotherapy response in lung cancer

Zejuan Li, Jianming Shao, Randall J. Olsen, Saro Kasparian et autres

us (code pays fourni par la source)